J Stroke.  2025 May;27(2):228-236. 10.5853/jos.2024.04098.

Low-Density Lipoprotein Cholesterol Level, the Lower the Better? Analysis of Korean Patients in the Treat Stroke to Target Trial

Affiliations
  • 1Department of Neurology, Gangnam Smart Neurology Clinic, Seoul, Korea
  • 2Department of Neurology, Gimcheon Jeil Hospital, Gimcheon, Korea
  • 3Department of Neurology, Dong-A University Hospital, Busan, Korea
  • 4Department of Neurology, College of Medicine, Pusan National University Hospital, Busan, Korea
  • 5Department of Neurology, Ewha Womans University, Seoul Hospital, Seoul, Korea
  • 6Department of Neurology, Soonchunhyang University College of Medicine, Seoul, Korea
  • 7Department of Neurology, Inje University Busan Paik Hospital, Busan, Korea
  • 8Department of Neurology, Kyungpook National University Hospital, Daegu, Korea
  • 9Department of Neurology, Yonsei University College of Medicine, Seoul, Korea
  • 10Department of Neurology, Chonnam National University Medical School & Hospital, Gwangju, Korea
  • 11Department of Neurology, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Korea
  • 12Department of Neurology, Hallym University Sacred Heart Hospital, Anyang, Korea
  • 13Department of Neurology, Inje University Ilsan Paik Hospital, Ilsan, Korea
  • 14Department of Neurology, Samsung Medical Center, Seoul, Korea
  • 15Department of Neurology and Anatomy, Hospital and College of Medicine, Chungnam National University, Daejeon, Korea
  • 16Department of Neurology, Gangneung Asan Hospital, University of Ulsan, Gangneung, Korea

Abstract

Background and Purpose
The Treat Stroke to Target (TST) was a randomized clinical trial involving French and Korean patients demonstrating that a lower low-density lipoprotein cholesterol (LDL-C, <70 mg/dL) target group (LT) experienced fewer cerebro-cardiovascular events than a higher target (90–110 mg/dL) group (HT). However, whether these results can be applied to Asian patients with different ischemic stroke subtypes remains unclear.
Methods
Patients from 14 South Korean centers were analyzed separately. Patients with ischemic stroke or transient ischemic attack with evidence of atherosclerosis were randomized into LT and HT groups. The primary endpoint was a composite of ischemic stroke, myocardial infarction, coronary or cerebral revascularization, and cardiovascular death.
Results
Among 712 enrolled patients, the mean LDL-C level was 71.0 mg/dL in 357 LT patients and 86.1 mg/dL in 355 HT patients. The primary endpoint occurred in 24 (6.7%) of LT and in 31 (8.7%) of HT group patients (adjusted hazard ratio [HR]=0.78; 95% confidence interval [CI]=0.45–1.33, P=0.353). Cardiovascular events alone occurred significantly less frequently in the LT than in the HT group (HR 0.26, 95% CI 0.09–0.80, P=0.019), whereas there were no significant differences in ischemic stroke events (HR 1.12, 95% CI 0.60–2.10, P=0.712). The benefit of LT was less apparent in patients with small vessel disease and intracranial atherosclerosis than in those with extracranial atherosclerosis.
Conclusion
In contrast to the French TST, the outcomes in Korean patients were neutral. Although LT was more effective in preventing cardiovascular diseases, it was not so in stroke prevention, probably attributed to the differences in stroke subtypes. Further studies are needed to elucidate the efficacy of statins and appropriate LDL-C targets in Asian patients with stroke.

Keyword

Ischemic stroke; LDL cholesterol; Target; Prevention; Asia
Full Text Links
  • JOS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2025 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr